deltatrials
Terminated PHASE2 NCT00268242

Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia

A Phase II Study of Gemcitabine/ Mitoxantrone in Patients With Acute Myeloid Leukemia in First Relapse

Sponsor: Duke University

Conditions Leukemia
Interventions Gemcitabine Hydrochloride Mitoxantrone Hydrochloride
Updated 9 times since 2017 Last updated: Jan 24, 2018 Started: Jan 31, 2006 Primary completion: Aug 31, 2010 Completion: Jul 31, 2011

This PHASE2 trial investigates Leukemia and is currently terminated or withdrawn. Duke University leads this study, which shows 9 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  5. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 4 earlier versions

  1. Jun 2018 — Nov 2020 [monthly]

    Terminated PHASE2

  2. May 2018 — Jun 2018 [monthly]

    Terminated PHASE2

  3. Aug 2017 — May 2018 [monthly]

    Terminated PHASE2

  4. Jan 2017 — Aug 2017 [monthly]

    Terminated PHASE2

    First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Duke University
  • National Cancer Institute (NCI)
  • The Cleveland Clinic
Data source: The Cleveland Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Cleveland, United States
  • • Durham, United States